|
1
|
Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.
|
J Clin Invest
|
2005
|
2.36
|
|
2
|
A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine.
|
Clin Rheumatol
|
2011
|
2.24
|
|
3
|
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.
|
Arthritis Rheum
|
2012
|
2.21
|
|
4
|
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.
|
J Rheumatol
|
2012
|
1.97
|
|
5
|
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis.
|
Rheumatology (Oxford)
|
2010
|
1.88
|
|
6
|
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.
|
Clin Immunol
|
2012
|
1.74
|
|
7
|
Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells.
|
J Immunol
|
2006
|
1.63
|
|
8
|
Differential effects of interleukin-4 in peptide induced autoimmunity.
|
Clin Immunol
|
2003
|
1.62
|
|
9
|
Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance.
|
Arthritis Rheum
|
2007
|
1.62
|
|
10
|
Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease.
|
J Immunol
|
2009
|
1.55
|
|
11
|
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.
|
Arthritis Res Ther
|
2009
|
1.54
|
|
12
|
Neutrophil gelatinase-associated lipocalin is instrumental in the pathogenesis of antibody-mediated nephritis in mice.
|
Arthritis Rheum
|
2012
|
1.53
|
|
13
|
Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis.
|
J Immunol
|
2007
|
1.49
|
|
14
|
Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies.
|
J Immunol
|
2002
|
1.49
|
|
15
|
Diffuse calcifications of the spleen: a novel association with systemic lupus erythematosus.
|
Semin Arthritis Rheum
|
2010
|
1.49
|
|
16
|
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.
|
J Immunol
|
2006
|
1.43
|
|
17
|
Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis.
|
Arthritis Rheum
|
2007
|
1.42
|
|
18
|
TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus.
|
J Immunol
|
2007
|
1.42
|
|
19
|
Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential.
|
Arthritis Rheum
|
2005
|
1.41
|
|
20
|
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway.
|
J Immunol
|
2009
|
1.40
|
|
21
|
BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.
|
Arthritis Rheum
|
2005
|
1.33
|
|
22
|
Necrotizing fasciitis in systemic lupus erythematosus.
|
Semin Arthritis Rheum
|
2007
|
1.27
|
|
23
|
Urinary TWEAK and the activity of lupus nephritis.
|
J Autoimmun
|
2007
|
1.21
|
|
24
|
TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells.
|
Cytokine
|
2009
|
1.20
|
|
25
|
The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity.
|
Front Biosci
|
2004
|
1.18
|
|
26
|
Role of TWEAK in lupus nephritis: a bench-to-bedside review.
|
J Autoimmun
|
2012
|
1.15
|
|
27
|
Metabolic disturbances associated with systemic lupus erythematosus.
|
PLoS One
|
2012
|
1.15
|
|
28
|
Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells.
|
Arthritis Rheum
|
2006
|
1.14
|
|
29
|
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?
|
Arthritis Rheum
|
2004
|
1.13
|
|
30
|
High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups.
|
Arthritis Rheum
|
2009
|
1.11
|
|
31
|
Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis.
|
Arthritis Res Ther
|
2012
|
1.10
|
|
32
|
Commentary on "The risky business of studying prognosis".
|
J Rheumatol
|
2013
|
1.09
|
|
33
|
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.
|
J Immunol
|
2011
|
1.08
|
|
34
|
Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis.
|
Ann N Y Acad Sci
|
2007
|
1.06
|
|
35
|
Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.
|
Immunol Lett
|
2008
|
1.04
|
|
36
|
Association of alpha-actinin-binding anti-double-stranded DNA antibodies with lupus nephritis.
|
Arthritis Rheum
|
2006
|
1.03
|
|
37
|
Urinary biomarkers in lupus nephritis.
|
Clin Rev Allergy Immunol
|
2011
|
1.03
|
|
38
|
Reversible posterior leukoencephalopathy in connective tissue diseases.
|
Semin Arthritis Rheum
|
2006
|
1.02
|
|
39
|
The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis.
|
Autoimmun Rev
|
2007
|
1.01
|
|
40
|
The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies.
|
J Autoimmun
|
2012
|
1.01
|
|
41
|
Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis.
|
Clin Dev Immunol
|
2012
|
0.99
|
|
42
|
Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis.
|
J Immunol
|
2010
|
0.99
|
|
43
|
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
0.98
|
|
44
|
The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus.
|
J Biomed Biotechnol
|
2011
|
0.97
|
|
45
|
Alpha-actinin immunization elicits anti-chromatin autoimmunity in nonautoimmune mice.
|
J Immunol
|
2007
|
0.95
|
|
46
|
TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis.
|
Immunol Lett
|
2009
|
0.94
|
|
47
|
Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway.
|
J Autoimmun
|
2013
|
0.94
|
|
48
|
Depression is an early disease manifestation in lupus-prone MRL/lpr mice.
|
J Neuroimmunol
|
2009
|
0.94
|
|
49
|
Mimotopes for lupus-derived anti-DNA and nucleosome-specific autoantibodies selected from random peptide phage display libraries: facts and follies.
|
J Immunol Methods
|
2004
|
0.94
|
|
50
|
TWEAK and the progression of renal disease: clinical translation.
|
Nephrol Dial Transplant
|
2014
|
0.91
|
|
51
|
Autoantibodies in lupus: culprits or passive bystanders?
|
Autoimmun Rev
|
2011
|
0.91
|
|
52
|
Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases.
|
Arthritis Res Ther
|
2010
|
0.91
|
|
53
|
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.
|
Arthritis Rheumatol
|
2014
|
0.91
|
|
54
|
The pathogenesis, diagnosis and treatment of lupus nephritis.
|
Curr Opin Rheumatol
|
2014
|
0.90
|
|
55
|
Sex and autoantibody titers determine the development of neuropsychiatric manifestations in lupus-prone mice.
|
J Neuroimmunol
|
2010
|
0.90
|
|
56
|
The constant region affects antigen binding of antibodies to DNA by altering secondary structure.
|
Mol Immunol
|
2013
|
0.88
|
|
57
|
Anti-alpha-actinin antibodies: a new marker of lupus nephritis.
|
Autoimmun Rev
|
2007
|
0.88
|
|
58
|
Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin.
|
J Immunol
|
2006
|
0.87
|
|
59
|
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.
|
Arthritis Rheum
|
2013
|
0.87
|
|
60
|
Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus.
|
Autoimmun Rev
|
2004
|
0.86
|
|
61
|
IgG3 deficiency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice.
|
Biol Direct
|
2012
|
0.86
|
|
62
|
The New York City Rheumatology Objective Structured Clinical Examination: five-year data demonstrates its validity, usefulness as a unique rating tool, objectivity, and sensitivity to change.
|
Arthritis Rheum
|
2009
|
0.85
|
|
63
|
Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.85
|
|
64
|
TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.
|
J Neuroinflammation
|
2013
|
0.85
|
|
65
|
Racial differences in gait velocity in an urban elderly cohort.
|
J Am Geriatr Soc
|
2012
|
0.85
|
|
66
|
Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase.
|
Immunol Lett
|
2008
|
0.84
|
|
67
|
A peptide DNA surrogate accelerates autoimmune manifestations and nephritis in lupus-prone mice.
|
J Immunol
|
2002
|
0.83
|
|
68
|
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1.
|
J Clin Immunol
|
2006
|
0.82
|
|
69
|
B-cell biology.
|
Rheum Dis Clin North Am
|
2004
|
0.82
|
|
70
|
Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases.
|
Clin Immunol
|
2012
|
0.81
|
|
71
|
Improving outcomes in patients with lupus and end-stage renal disease.
|
Semin Dial
|
2013
|
0.80
|
|
72
|
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.
|
J Immunol
|
2008
|
0.79
|
|
73
|
Proliferative glomerulonephritis in lupus patients with human immunodeficiency virus infection: a difficult clinical challenge.
|
Semin Arthritis Rheum
|
2010
|
0.78
|
|
74
|
The role of anti-alpha-actinin antibodies in the pathogenesis and monitoring of lupus nephritis.
|
Arthritis Res Ther
|
2009
|
0.78
|
|
75
|
Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.
|
J Rheumatol
|
2011
|
0.78
|
|
76
|
Systemic lupus erythematosus.
|
Clin Dev Immunol
|
2012
|
0.78
|
|
77
|
High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.
|
J Clin Pathol
|
2012
|
0.78
|
|
78
|
JAK2 inhibition in murine systemic lupus erythematosus.
|
Immunotherapy
|
2012
|
0.77
|
|
79
|
Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.
|
JCI Insight
|
2017
|
0.76
|
|
80
|
Controversies in rheumatism and autoimmunity.
|
Autoimmun Rev
|
2011
|
0.75
|